Sumitomo Dainippon has a total of 103 patents globally, out of which 27 have been granted. Of these 103 patents, more than 68% patents are active. United States of America is where Sumitomo Dainippon has filed the maximum number of patents, followed by Canada and Mexico. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Sumitomo Dainippon.
Sumitomo Dainippon was founded in the year 2020. The Company manufactures, develops and sells pharmaceutical, food ingredients, food additives, veterinary medicines, and diagnostics products.
Do read about some of the most popular patents of Sumitomo Dainippon which have been covered by us in this article and also you can find Sumitomo Dainippon patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Sumitomo Dainippon patent portfolio.
How many patents does Sumitomo Dainippon have?
Sumitomo Dainippon has a total of 103 patents globally. These patents belong to 44 unique patent families. Out of 103 patents, 71 patents are active.
How Many Patents did Sumitomo Dainippon File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
Year of Patents Filing or Grant | Sumitomo Dainippon Applications Filed | Sumitomo Dainippon Patents Granted |
2022 | 5 | 4 |
2021 | 10 | 4 |
2020 | 17 | 6 |
2019 | 10 | 1 |
2018 | 12 | 1 |
2017 | 8 | 6 |
2016 | 13 | – |
2015 | 4 | 1 |
2014 | 5 | 1 |
2013 | 1 | – |
2012 | 2 | – |
Explore the top-performing drugs that dominate the Pharmaceutical Industry
Patent Number | Company | Product | Brand | Revenue | Patent Expiry Date |
US9174975 | Sumitomo Pharma | Lurasidone Hydrochloride | Latuda | $1.75B | Jun-26 |
US7612199 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
US7902206 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
US8158644 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
US7371727 | Ironwood Pharma | Linaclotide | Linzess | $1.00B | Mar-25 |
Want to know which drugs are making over $1 Billion annually?
How many Sumitomo Dainippon patents are Alive/Dead?
How Many Patents did Sumitomo Dainippon File in Different Countries?
Countries in which Sumitomo Dainippon Filed Patents
Country | Patents |
United States Of America | 23 |
Canada | 22 |
Mexico | 13 |
Hong Kong (S.A.R.) | 13 |
Israel | 5 |
Europe | 4 |
Singapore | 3 |
New Zealand | 2 |
Austria | 2 |
Philippines | 1 |
Indonesia | 1 |
Spain | 1 |
Malaysia | 1 |
Italy | 1 |
Where are Research Centres of Sumitomo Dainippon Patents Located?
10 Best Sumitomo Dainippon Patents
US20120058997A1 is the most popular patent in the Sumitomo Dainippon portfolio. It has received 30 citations so far from companies like Supergen, Tolero Pharmaceuticals and Califia Bio.
Below is the list of 10 most cited patents of Sumitomo Dainippon:
Publication Number | Citation Count |
US20120058997A1 | 30 |
US8877803B2 | 27 |
US7998966B2 | 27 |
US20110269772A1 | 19 |
US20080214558A1 | 11 |
US9732055B2 | 7 |
US9745278B2 | 6 |
US9834532B2 | 4 |
US9730909B2 | 4 |
CA2959951A1 | 4 |
What are Sumitomo Dainippon key innovation segments?
What Technologies are Covered by Sumitomo Dainippon?
The chart below distributes patents filed by Sumitomo Dainippon